The TCE pipeline is ever-growing and there are multiple different formats, engagers and costimulatory being studied in over 90 trials, with over a hundred projects in the preclinical stage. To treat hematological malignancies, the majority of pharmaceutical and biotech companies are focusing on lymphocyte-restricted tumor-associated antigens such as CD19, CD20, BCMA, CD33, and CD123.
The 5th Annual Cell Engager Summit will discover everything there is to know about the immune cell engager landscape, including clinical successes, prospective response predictors, and cutting-edge immune cell-based engager therapeutic discoveries. To increase safety (lower CRS) and efficacy (higher dose, better tumor penetration/accumulation, lower TMDD) in the solid tumor microenvironment, target tumor antigens (HER2, EGFR, etc.) and change co-stimulatory receptors (CD137/4-1BB, CD28). Use properly proven strategies to address effectiveness issues such as T-cell depletion in solid tumors (alternatives to CD3s, maybe NK engagers), toxicity in hematological malignancies (protease/ph-based cleavage), and toxicity in hematological tumors.
Continue reading at cell-engager-summit.com
April 24 to April 25, 2023
Zurich , Switzerland
Connecting innovation decision makers to authoritative information, institutions, people and insights.
Medigy accurately delivers healthcare and technology information, news and insight from around the world.
Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.
© 2023 Netspective Media LLC. All Rights Reserved.
Built on Mar 30, 2023 at 7:39am